William Townsend, EHA 2022: Final analysis of the GALLIUM study of obinutuzumab plus chemotherapy in follicular lymphoma
Dr William Townsend shares the latest data from the final analysis of the phase III GALLIUM study, which used the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab plus chemotherapy to follicular lymphoma. The study compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma.
The abstract ‘OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY’ (Abstract: S206) was was presented at the EHA2022 Congress, 9-12 June 2022.
- What are the unmet needs in the first-line treatment of patients with follicular lymphoma? (00:30-01:50)
- Could you give us a brief overview of the GALLIUM study and its efficacy and safety findings? (01:50-06:13)
- What have we learned from the final analysis of the GALLIUM study? (06:13-07:22)
- Which patients are most likely to benefit from obinutuzumab and in whom is it contraindicated? (07:22-08:35)
Disclosures: William Townsend is on the advisory board for: BMS, Roche and Takeda, and has received honoraria/honorarium from: BMS, Gilead, Incyte, Roche and Takeda.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 27th Congress of the European Hematology Association (EHA)
